MaaT013
Acute Graft-versus-Host Disease (aGvHD)
Key Facts
About MaaT Pharma
MaaT Pharma is a clinical-stage company focused on leveraging the gut microbiome to improve survival in cancer patients. Its core strategy is built on a differentiated 'full ecosystem' therapeutic platform, with lead candidate MaaT013 in Phase 3 for acute Graft-versus-Host Disease (aGvHD). The company has established integrated R&D and cGMP manufacturing capabilities and is publicly traded on Euronext Paris to fund its ambitious late-stage clinical programs.
View full company profileAbout MaaT Pharma
MaaT Pharma is a clinical-stage company focused on leveraging the gut microbiome to improve survival in cancer patients. Its core strategy is built on a differentiated 'full ecosystem' therapeutic platform, with lead candidate MaaT013 in Phase 3 for acute Graft-versus-Host Disease (aGvHD). The company has established integrated R&D and cGMP manufacturing capabilities and is publicly traded on Euronext Paris to fund its ambitious late-stage clinical programs.
View full company profileTherapeutic Areas
Other Acute Graft-versus-Host Disease (aGvHD) Drugs
| Drug | Company | Phase |
|---|---|---|
| AC-003 | Accro Bioscience | Phase 1b |
| Tregalizumab | CD4 Therapeutics | Phase 2 |
| ABCB5+ MSCs | RHEACELL | Pre-clinical development |
| Apraglutide | Ironwood Pharmaceuticals | Phase 2 |
| Itolizumab (EQ001) | Equillium | Phase 1b |